Orthocell logo

Orthocell(ASX) OCC

Market CapA$187.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)+92%
5 Year+34%
1 Year-52%
1 Month-5%
A$0.69
-0.72%
-0.00Today
Orthocell last closing stock price
MetricPriceDate
Last closeAUD 0.692026-10-09
Orthocell stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-9.21%AUD 0.762026-10-02
1 month-4.83%AUD 0.732026-09-09
3 month-18.34%AUD 0.852026-07-10
Year to date-36.41%AUD 1.092025-12-31
1 year-52.08%AUD 1.442025-10-09
3 year+97.14%AUD 0.352023-10-10
5 year+33.98%AUD 0.522021-10-08
Since inception+91.67%AUD 0.362014-08-12

Orthocell Financials at a Glance

Market Cap

A$187.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$17.81M

Net Income (TTM)

-A$22.48M

EPS (TTM)

-A$0.05

P/E Ratio

-13.02

Dividend

A$0.00

Beta (Volatility)

-0.10 (Low)

Price

A$0.69

Volume

134,625

Open

A$0.70

Previous Close

A$0.69

Daily Range

A$0.69 - A$0.71

52-Week Range

A$0.67 - A$1.51

Estimated Earnings Date

Feb 19, 2027

OCC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Orthocell

Orthocell Limited is a regenerative medicine company based in Murdoch, Australia, focused on developing advanced cell therapies and biological medical devices. Established in 2006, the company aims to enhance the healing of bone and soft tissue injuries through innovative products.

Products and Services
  • CelGro: A collagen medical device for surgical repair across various indications
  • Ortho-ATI: A specialized cell therapy for chronic tendon injuries
  • Striate+: A biodegradable collagen membrane for dental tissue regeneration
Growth Outlook
  • Recent revenue growth of 10.5% in the last quarter indicates strong market demand
  • Expansion into new markets is expected to drive future revenue increases
  • Ongoing R&D investments aim to enhance product offerings and efficacy
Financial Highlights
  • Latest quarterly revenue of AUD 5.99 million reflects a significant increase
  • Cash and short-term investments total AUD 44.15 million, providing financial stability
  • Current ratio of 5.97 indicates strong liquidity and ability to meet short-term obligations
AI Generated • Sep 19, 2026

Industry

Biotechnology

CEO

Paul Frederick Anderson

Headquarters

Murdoch, WA 6150, AU

OCC Financials

Key Financial Metrics (TTM)

Gross Margin

27.87%

Operating Margin

-161.15%

Net Income Margin

-121.98%

Return on Equity

-36.83%

Return on Capital

-51.12%

Return on Assets

-25.39%

Earnings Yield

-7.68%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$187.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

272.39M

Volume

134.63K

Avg. Volume

283.43K

Financials (TTM)

Gross Profit

A$6.76M

Operating Income

-A$32.96M

EBITDA

-A$28.77M

Operating Cash Flow

-A$22.00M

Capital Expenditure

-A$1.37M

Free Cash Flow

-A$23.37M

Cash & ST Invst.

A$44.15M

Total Debt

A$1.55M

Orthocell Performance Analysis

Orthocell annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 4,243,069177.0%
20242024-06-30AUD 5,315,37525.3%
20252025-06-30AUD 7,846,78847.6%
20262026-06-30AUD 11,407,15645.4%
Orthocell sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-38.5%
Q42025-06-3066.1%
Q22025-12-3135.7%
Q42026-06-3010.6%
Orthocell annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.03-32.3%
20242024-06-30AUD -0.0412.3%
20252025-06-30AUD -0.047.9%
20262026-06-30AUD -0.0537.5%
Orthocell sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3137.5%
Q42025-06-30-398.3%
Q22025-12-3129.8%
Q42026-06-30-52.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$5.99M

+53.2%

Gross Profit

A$2.12M

-31.4%

Gross Margin

35.38%

N/A

Market Cap

A$187.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$5.08M

N/A

Employees

37

N/A

Net Income

-A$8.70M

-346.0%

EBITDA

-A$8.68M

-83.7%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$44.15M

+114.2%

Total Debt

A$1.55M

+124.8%

Accounts Receivable

A$2.85M

+147.6%

Inventory

A$1.69M

+43.7%

Long Term Debt

A$572.27K

+5.8%

Short Term Debt

A$977.91K

+556.5%

Return on Assets

-25.39%

N/A

Return on Invested Capital

-39.56%

N/A

Free Cash Flow

-A$5.34M

-138.2%

Operating Cash Flow

-A$4.33M

-151.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ARX.AXAroa Biosurgery Limited
A$0.52+0.00%
TTX.AXTetratherix Ltd.
A$6.34-6.07%
TRP.AXTissue Repair Ltd
A$0.09+0.00%
OSX.AXOsteopore Limited
A$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.18-9.81%
WFFWf
$12.29+499.51%
VZVerizon Communications
$41.65-8.75%
SPCXSpace Exploration Technologies
$162.57+1.25%

Questions About OCC

What is the current price of Orthocell?

Orthocell is trading at A$0.69 per share.

What is the 52-week range for Orthocell?

Over the past 52 weeks, Orthocell has traded between A$0.67 and A$1.51.

How much debt does Orthocell have?

As of the most recent reporting period, Orthocell reported total debt of A$1.55M.

How much cash does Orthocell have on hand?

Orthocell reported A$9.45M in cash and cash equivalents in its most recent financial results.

What is Orthocell’s dividend yield?

Orthocell does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.